Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    C-200-001
Previous Study | Return to List | Next Study

A Research Study to See How Well an Eye Drop, SURF-200 (0.02% and 0.04% Betamethasone Sodium Phosphate), Works, What Side Effects There Are, and to Compare it With Vehicle (Placebo) in Subjects Diagnosed With Dry Eye Disease and Experiencing An Episodic Flare-Up

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04734210
Recruitment Status : Recruiting
First Posted : February 2, 2021
Last Update Posted : July 27, 2021
Sponsor:
Information provided by (Responsible Party):
Surface Pharmaceuticals, Inc.

Brief Summary:

SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.

The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.


Condition or disease Intervention/treatment Phase
Dry Eye Disease Drug: 0.02% Betamethasone Sodium Phosphate Drug: 0.04% Betamethasone Sodium Phosphate Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Actual Study Start Date : January 7, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : March 2023


Arm Intervention/treatment
Experimental: SURF-200 (0.02% betamethasone sodium phosphate in vehicle)
One drop twice daily (BID) in the study eye for 14 days.
Drug: 0.02% Betamethasone Sodium Phosphate
topical corticosteroid solution

Experimental: SURF-200 (0.04% betamethasone sodium phosphate in vehicle)
One drop BID in the study eye for 14 days.
Drug: 0.04% Betamethasone Sodium Phosphate
topical corticosteroid solution

Placebo Comparator: Vehicle
One drop BID in the study eye for 14 days.
Drug: Placebo
topical vehicle solution




Primary Outcome Measures :
  1. UNC DEMS Score [ Time Frame: Day 8 ]
    A minimum reduction of 1 unit in patient-reported dry eye disease symptoms and reduction of impact of symptoms with SURF-200 as compared to vehicle (as measured by the University of North Carolina [UNC] Dry Eye Management Scale [DEMS]).


Secondary Outcome Measures :
  1. UNC DEMS Score [ Time Frame: Day 15 ]
    A minimum reduction of 1 unit in patient-reported dry eye disease symptoms and reduction of impact of symptoms with SURF-200 as compared to vehicle (as measured by the University of North Carolina [UNC] Dry Eye Management Scale [DEMS]).

  2. Conjunctival Hyperemia Assessment [ Time Frame: Day 8 ]
    A minimum reduction of 0.5 points in conjunctival hyperemia with SURF-200 as compared to vehicle using the Conjunctival Hyperemia Assessment 4 point scale (0-3) in the study eye.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects 18 years of age and older who have a diagnosis of dry eye disease and experiencing an episodic flare up. Criteria for the diagnosis must include the following:

    1. UNC DEMS score of greater than or equal to 5 but less than or equal to 9
    2. Conjunctival hyperemia score of greater than or equal to 2 in the study eye when using the conjunctival hyperemia reference photos
    3. Schirmer's Tear Test score (with anesthesia) greater than 1 mm but less than or equal to12 mm in the study eye
  2. Subjects must be able to understand and sign the Informed Consent Form (ICF).
  3. Female subjects of childbearing potential must agree to and submit a negative urine pregnancy test before any study-specific procedures are performed. The subjects must be using and continue to use a suitable method of contraception for the duration of the study: spermicide with barrier, oral contraceptive, transdermal contraceptive, injectable or implantable contraceptive, intrauterine device (IUD), abstinence or surgical sterilization of a partner. If a subject is not of childbearing potential (e.g., has been postmenopausal for at least 12 months or is premenarchal, or has undergone a hysterectomy, bilateral oophorectomy or a bilateral tubal ligation), a urine pregnancy test and use of a suitable method of contraception for the duration of the study will not be required.
  4. Subjects must have a best-corrected visual acuity (BCVA) of at least +1.0 log of the minimum angle of resolution (logMAR) (Snellen equivalent of 20/200) in the non-study eye (fellow eye).
  5. Subjects must have an intraocular pressure (IOP) of >8 mmHg and ≤22 mmHg in the study eye.
  6. Subjects who are on Restasis, Xiidra or other cyclosporine ophthalmic eye drops must be on a stable dose for at least 4 months prior to Screening Visit 1 (Day -14 to Day 0) and remain compliant with the use of these medications throughout the duration of this study.
  7. Subjects who are on artificial tears, oral antihistamines, beta blockers and diuretics must be on a stable dose for at least 1 month prior to Screening Visit 1 (Day -14 to Day 0) and remain compliant with the use of these medications throughout the duration of this study.
  8. Subjects must be willing and able to attend all study visits and follow all instructions.
  9. Subjects must be able to self-instill the study drug (if unable, a caregiver must be available to instill all doses of the study drug).
  10. Have a history of use or desire to use an eye drop for dry eye symptoms for longer than the past 6 months.

Exclusion Criteria:

  1. Females who are pregnant or nursing or planning to become pregnant during the study. Females of childbearing potential (not surgically sterilized or postmenopausal) may not participate in the study if they do not agree to use adequate birth control methods for the duration of the study.
  2. Use of contact lenses in either eye during the study. Contact lens wear must have been discontinued at least 2 weeks prior to Baseline/Randomization Visit 2 (Day 1).
  3. Use of corticosteroids or nonsteroidal anti-inflammatory agents (NSAID) (except oral doses of aspirin at 81 mg/day or lower) within 2 weeks of the initiation of study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.
  4. Inhaled, ingested, sublingual, transdermal or topical products containing marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) within 7 days of the first dose of study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.
  5. Presence or history of treatment with systemic immunosuppressive or chemotherapeutic agents.
  6. History of high IOP response to steroids.
  7. Participated in an ophthalmic investigational product clinical trial within 30 days of Screening Visit 1 (Day -14 to Day 0).
  8. Active collagen vascular disorder or autoimmune disease.
  9. A condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
  10. Known hypersensitivity to any component of the study drug or procedural medications.
  11. Known hypersensitivity to steroids.
  12. Any active corneal epithelial/stromal pathology noted in the study eye at Screening Visit 1 (Day -14 to Day 0).
  13. Any history of corneal surgery in the study eye (including corneal crosslinking, radial keratotomy, corneal transplant, or LASIK).
  14. Any ocular surgery in the study eye within the past year.
  15. Subject has punctal occlusion with any modality or a change in punctal plug status in either eye within the 3 months prior to Screening Visit 1 (Day -14 to Day 0).
  16. Subject has a history of glaucoma.
  17. Subject has a history of herpes simplex infection in either eye.
  18. Subject has active corneal, conjunctival or canalicular pathology (including ocular infection [bacterial, viral or fungal]) in either eye. Specifically, active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and mycobacterial infection of either eye and fungal diseases of the ocular structures (such as fungal keratitis).
  19. Subject has thinning of the cornea or sclera in the study eye.
  20. Subject has active anterior blepharitis in the study eye.
  21. Subject has a history of uveitis in the study eye.
  22. Subject is suffering from alcohol and/or drug abuse.
  23. Subject has tested positive for the COVID-19 virus within 30 days prior to Screening Visit 1 (Day -14 to Day 0).
  24. Subject has previously received treatment in this study protocol.
  25. Subject is taking a medication, that in the opinion of the investigator, might interfere with the study parameters.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04734210


Contacts
Layout table for location contacts
Contact: Sponsor Company's Vice President of Clinical Operations (925) 494-3660 ext 18 cbaenziger@surfaceophthalmics.com
Contact: Sponsor Company's Director of Clinical Operations (925) 494-3660 ext 7 kmorrison@surfaceophthalmics.com

Locations
Show Show 25 study locations
Sponsors and Collaborators
Surface Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Chair: Kamran Hosseini, MD, PhD Surface Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Surface Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04734210    
Other Study ID Numbers: C-200-001
First Posted: February 2, 2021    Key Record Dates
Last Update Posted: July 27, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Eye Diseases
Lacrimal Apparatus Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone sodium phosphate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents